Vitiligo is a chronic autoimmune skin condition that causes the loss of melanocytes, leading to lighter or white patches on the skin. It can affect people of all ages and may involve the face, hands, feet, and other areas of the body.

A 2024 systematic review estimated that physician- or dermatologist-diagnosed vitiligo affects approximately 28.5 million people worldwide, with an estimated lifetime prevalence of 0.36%.

At Bay Biosciences, we provide high-quality vitiligo research samples, including serum, plasma, peripheral blood mononuclear cells (PBMCs), and other human biospecimens for research.

Vitiligo Samples for research

Understanding Vitiligo

Vitiligo is an acquired autoimmune condition that causes patches of skin to lose their natural color. It develops when melanocytes, the cells that produce melanin, are damaged or destroyed.

Melanin gives skin, hair, and eyes their color. It also helps protect the skin from ultraviolet radiation.

However, when melanocytes are lost, affected areas may appear lighter than the surrounding skin and may eventually become completely white.

The condition is not contagious and does not spread through physical contact.

However, its course can be unpredictable. Some patches remain stable for years, while others may gradually expand or appear in new areas.

Symptoms of Vitiligo

Common symptoms and features generally include:

  • Pale or white patches on the skin
  • Depigmentation on the hands, face, arms, legs, or lips
  • White or prematurely graying hair in affected areas
  • Loss of pigment around the eyes or mouth
  • Depigmentation of the eyebrows or eyelashes
  • Increased sensitivity to sunlight
  • Patches that expand or join together
  • Loss of pigment following skin injury
  • Emotional distress or reduced self-esteem

Vitiligo usually does not cause pain, itching, or scaling. However, affected skin can burn more easily when exposed to sunlight.

Some individuals with vitiligo may also develop eye inflammation, hearing changes, or other autoimmune conditions.

It’s also important to highlight here that the appearance and progression of the condition can vary significantly between patients.

What Causes Vitiligo?

What causes vitiligo is not fully understood.

However, researchers believe that several genetic, immune-related, and environmental factors may contribute to the destruction of melanocytes.

Firstly, an autoimmune response is considered one of the main mechanisms involved. In people with vitiligo, immune cells may mistakenly recognize melanocytes as harmful and attack them.

This process can lead to the loss of pigment-producing cells.

Secondly, genetic factors may influence susceptibility.

People with a family history of vitiligo or other autoimmune disorders may have an increased likelihood of developing the condition. However, having a genetic risk factor does not mean that a person will definitely develop vitiligo.

Thirdly, oxidative stress may contribute to melanocyte damage. Oxidative stress occurs when the production of reactive oxygen molecules exceeds the body’s antioxidant defenses.

Finally, environmental triggers may contribute to disease onset or progression. Potential triggers include severe sunburn, skin injury, emotional stress, and exposure to certain chemicals.

These factors may not cause vitiligo in every person but may contribute to disease activity in susceptible individuals.

Risk Factors for Vitiligo

Several factors may increase the likelihood of developing vitiligo.

For example, family history may influence risk.

Some individuals with vitiligo have a close relative with the same condition or another autoimmune disease.

Similarly, having an existing autoimmune disorder may increase susceptibility. Vitiligo has been associated with autoimmune thyroid disease, type 1 diabetes, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, Addison disease, and pernicious anemia.

Researchers continue to investigate how genetic predisposition, immune-cell activity, environmental exposure, and cellular stress interact in the development of vitiligo.

 

Diagnosis of Vitiligo

The diagnosis of vitiligo generally begins with a medical history and physical examination of the skin.

Firstly, a dermatologist may examine the size, shape, location, and distribution of depigmented patches.

Secondly, a Wood’s lamp may be used. This ultraviolet light can make areas of pigment loss more visible, particularly in people with lighter skin.

Thirdly, the physician may ask about family history, autoimmune diseases, recent skin injury, sunburn, medication exposure, and the timing of patch development.

In selected cases, blood tests may be recommended to investigate associated autoimmune conditions, particularly thyroid disease.

A skin biopsy is not always necessary but may be used when the diagnosis is uncertain, or another skin condition needs to be excluded.

These diagnostic approaches may also support the collection and characterization of vitiligo autoimmune research samples for laboratory investigations.

Treatment of Vitiligo

There is currently no universally effective cure for vitiligo.

However, several treatments may help restore pigment, reduce the visibility of patches, or slow the development of new areas of depigmentation.

Sunscreen and Skin Protection

Depigmented skin contains less melanin and is more vulnerable to ultraviolet radiation.

Sunscreen, protective clothing, shade, and other sun-protection measures can help reduce the risk of sunburn and further skin damage.

Phototherapy

Narrowband ultraviolet B (NB-UVB) phototherapy is commonly used for widespread or progressive vitiligo. Treatment involves controlled exposure to specific wavelengths of UVB light under medical supervision.

Phototherapy may stimulate pigment production and encourage repigmentation in some patients. Results vary depending on the affected body area, disease duration, and individual response.

Topical Corticosteroids

Topical corticosteroids may help reduce local inflammation and may support repigmentation in selected patients. Their use requires medical supervision, particularly on the face and other areas where prolonged treatment may cause skin thinning or other side effects.

Calcineurin Inhibitors

Topical tacrolimus and pimecrolimus may be used for certain areas of vitiligo, including the face and skin folds. These medicines affect immune signaling and may help reduce immune-related melanocyte damage.

Surgical and Cosmetic Approaches

In selected stable cases, procedures such as skin grafting, blister grafting, or melanocyte transplantation may be considered. Cosmetic camouflage and medical tattooing may also help reduce the visible contrast between affected and unaffected skin.

Treatment selection depends on disease extent, location, progression, age, general health, and patient preference.

Frequently Asked Questions

Why are Vitiligo Blood Samples for Research important?

Vitiligo blood samples for research are important because they support investigations into circulating immune markers, cytokines, chemokines, autoantibodies, gene-expression patterns, and other biological indicators.

What are vitiligo PBMC samples used to study?

Vitiligo PBMC samples may be used to investigate immune-cell activation, T-cell responses, cytokine production, inflammation, and other mechanisms associated with autoimmune melanocyte destruction.

Are your research samples ethically sourced?

Yes. All biospecimens available on our website are sourced with ethical guidelines in mind.

Supporting Your Research with Bay Biosciences

At Bay Biosciences, we provide high-quality vitiligo research samples and other human biospecimens to support autoimmune disease research, biomarker discovery, diagnostics, and therapeutic development.

Our comprehensive range of biospecimens includes:

If you have any questions, concerns, or special requests, please don’t hesitate to contact us.